4-溴苯并[b]噻吩-2-羧酸甲酯 | 360575-29-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 4-溴苯并[b]噻吩-2-羧酸甲酯
• 中文别名: 4-溴-1-苯并噻吩-2-羧酸甲酯；4-溴苯并噻吩-2-羧酸甲酯
• 英文名称: methyl 4-bromobenzo[b]thiophene-2-carboxylate
• 英文别名: methyl 4-bromo-1-benzothiophene-2-carboxylate
• CAS: 360575-29-7
• 化学式: C₁₀H₇BrO₂S
• 分子量: 271.134
• InChiKey: AOQIBJZMRMVKSH-UHFFFAOYSA-N

物化性质

• 熔点：
  105-108°
• 沸点：
  358.9±22.0 °C(Predicted)
• 密度：
  1.622

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-溴苯并[b]噻吩-2-羧酸甲酯 在 镍 四(三苯基膦)钯 、 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 20.0 ℃ 、275.79 kPa 条件下， 生成 N-carbamimidoyl-4-ethyl-1-benzothiophene-2-carboxamide
  参考文献：
  名称：

  4-Substituted (benzo[b]thiophene-2-carbonyl)guanidines as novel Na+/H+ exchanger isoform-1 (NHE-1) inhibitors

  摘要：

  A series of 4-substituted (benzo[b]thiophene-2-carbonyl)guanidines was synthesized and evaluated for the NHE-1 inhibitory activity and cardioprotective efficacy both in vitro and in vivo. Several analogs exhibited a strong inhibition on NHE-1, and which was generally well correlated with their cardioprotective efficacy. Especially the 4-nitro 20 and cyano 50 compounds excellently improved the cardiac function and reduced infarct size against ischemia/reperfusion injury. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.046
• 作为产物：
  描述：

  间溴氟苯 在 potassium carbonate 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-溴苯并[b]噻吩-2-羧酸甲酯
  参考文献：
  名称：

  4-Substituted (benzo[b]thiophene-2-carbonyl)guanidines as novel Na+/H+ exchanger isoform-1 (NHE-1) inhibitors

  摘要：

  A series of 4-substituted (benzo[b]thiophene-2-carbonyl)guanidines was synthesized and evaluated for the NHE-1 inhibitory activity and cardioprotective efficacy both in vitro and in vivo. Several analogs exhibited a strong inhibition on NHE-1, and which was generally well correlated with their cardioprotective efficacy. Especially the 4-nitro 20 and cyano 50 compounds excellently improved the cardiac function and reduced infarct size against ischemia/reperfusion injury. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.046

文献信息

• METHOD FOR PROMOTING PLANT GROWTH
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20150282482A1

  公开（公告）日：2015-10-08

  The present invention provides a method for promoting plant growth, which comprises treating a plant with a compound represented by the following Formula (1): provided that a method for promoting plant growth which comprises treating plants with a compound corresponding to any one of the following (1) to (8) is excluded: (1) Methyl 4-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, (2) Methyl 5-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, (3) Methyl 6-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, (4) Methyl 7-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, (5) Ethyl 4-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, (6) Ethyl 5-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, (7) Ethyl 6-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, and (8) Ethyl 7-(trifluoromethyl)benzo[b]thiophene-2-carboxylate.

  本发明提供了一种促进植物生长的方法，包括用下式表示的化合物处理植物： 只要排除用与以下任一化合物相对应的化合物处理植物的促进植物生长方法：(1) 甲基4-(三氟甲基)苯并[b]噻吩-2-羧酸酯，(2) 甲基5-(三氟甲基)苯并[b]噻吩-2-羧酸酯，(3) 甲基6-(三氟甲基)苯并[b]噻吩-2-羧酸酯，(4) 甲基7-(三氟甲基)苯并[b]噻吩-2-羧酸酯，(5) 乙基4-(三氟甲基)苯并[b]噻吩-2-羧酸酯，(6) 乙基5-(三氟甲基)苯并[b]噻吩-2-羧酸酯，(7) 乙基6-(三氟甲基)苯并[b]噻吩-2-羧酸酯，以及(8) 乙基7-(三氟甲基)苯并[b]噻吩-2-羧酸酯。
• 벤조치오펜 유도체 및 망막 질환의 예방 또는 치료를 위한 이들의 의약 용도
  申请人：J2H Biotech(주) 제이투에이치바이오텍 (주)(120140709000) Corp. No ▼ 134811-0312330BRN ▼143-81-27251

  公开号：KR20210031203A

  公开（公告）日：2021-03-19

  본 발명은 RIPK1 저해 활성을 가지는 신규한 벤조[b]치오펜 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 신규한 벤조[b]치오펜 유도체, 또는 이의 약학적으로 허용 가능한 염은 RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)의 억제 효과가 뛰어나므로, 황반변성을 포함하는 다양한 망막 질환의 치료 또는 예방에 유용하게 사용될 수 있다.

  这项发明涉及一种具有RIPK1抑制活性的新苯并[b]噻唑衍生物，其制备方法以及用作有效成分的药物组合物，用于预防或治疗与视网膜疾病有关的眼科药物。根据本发明，新的苯并[b]噻唑衍生物或其药学上可接受的盐具有出色的RIPK1（受体相互作用丝氨酸/苏氨酸蛋白激酶1）抑制作用，因此可以在治疗或预防包括黄斑变性在内的各种视网膜疾病中发挥有益作用。
• 신규한 벤조[b]싸이오펜 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
  申请人：The Industry & Academic Cooperation in Chungnam National University (IAC) 충남대학교산학협력단(220040084104) BRN ▼314-82-09264

  公开号：KR101515985B1

  公开（公告）日：2015-05-04

  본 발명은 신규한 메타논 유도체, 이의 제조방법, 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물에 관한 것으로, 본 발명에 따른 신규한 메타논 유도체, 이의 광학 이성질체, 또는 이의 약학적으로 허용가능한 염은 RIPK1(Receptor-interacting serine/threonine-protein kinase 1)의 억제 효과가 뛰어나므로, 이를 유효성분으로 함유하는 조성물은 색소성 망막염 (RP), 레베르 선천 흑암시 (LCA), 스타가르트병, 어셔 증후군, 맥락막 결여, 로드-콘 또는 콘-로드 디스트로피, 섬모병증, 미토콘드리아 장애, 진행성 망막 위축증, 퇴행성 망막 질환, 노화-관련된 황반 변성 (AMD), 습성 AMD, 건성 AMD, 지도상 위축증, 가족형 또는 획득 황반병증, 망막 광수용체 질환, 망막 색소 상피-계 질환, 당뇨병성 망막증, 낭포성 황반 부종, 포도막염, 망막박리, 외상성 망막 손상, 의원성 망막 손상, 황반 원공, 황반 모세관확장증, 신경절 세포 질환, 시신경 세포 질환, 녹내장, 시신경병증, 허혈성 망막 질환, 미숙아 망막증, 망막 혈관 폐색, 가족형 마크로아뉴리즘, 망막 혈관 질환, 안혈관 질환, 녹내장으로 인한 망막신경세포 퇴화, 또는 허혈성 시신경병증 등의 망막 질환의 예방 또는 치료용 약학적 조성물로 유용하게 사용될 수 있다.

  本发明涉及一种新型的甲酮衍生物，其制备方法，以及用作视网膜疾病的预防或治疗药物组合物，根据本发明，由于新型的甲酮衍生物，其光学异构体或药学上可接受的盐具有出色的RIPK1（受体相互作用丝氨酸/苏氨酸蛋白激酶1）抑制作用，因此包含其作为有效成分的组合物可用作色素性视网膜炎（RP），勒贝尔先天性黑暗症（LCA），斯塔格特病，阿什尔综合征，脉络膜缺损，罗德-锥或锥-罗德萎缩症，圆锥病变，线粒体疾病，进行性视网膜萎缩症，变性性视网膜疾病，与衰老相关的黄斑变性（AMD），湿性AMD，干性AMD，地图样萎缩症，家族性或获得性黄斑病变，视网膜光感受器疾病，视网膜色素上皮-间质疾病，糖尿病性视网膜病变，囊性黄斑水肿，葡萄膜炎，视网膜脱离，创伤性视网膜损伤，特发性视网膜损伤，黄斑囊肿，黄斑血管扩张症，神经节细胞疾病，视神经细胞疾病，青光眼，视神经病变，缺血性视网膜疾病，早产儿视网膜病变，视网膜血管闭塞，家族性巨细胞动脉炎，视网膜血管疾病，眼内血管疾病，由青光眼引起的视神经细胞退化，或缺血性视神经病变等视网膜疾病的预防或治疗药物组合物可被有效地使用。
• Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents
  申请人：——

  公开号：US20030166628A1

  公开（公告）日：2003-09-04

  The present invention relates to certain novel substituted dihydroimidazo[2,1-b]thiazole and dihydro-5H-thiazolo[3,2-a]pyrimidine compounds of Formula (I) including pharmaceutically acceptable salts thereof in which have affinity for 5-HT 1A receptors and which inhibits neuronal reuptake of 5-hydroxytryptamine and/or noradrenaline, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, stress, as an aid to smoking cessation and in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or in which there is neurological damage such as stroke, brain trauma, cerebral ischaemia, head injuries and haemorrhage.

  本发明涉及某些新颖的Formula (I)中的取代二氢咪唑[2,1-b]噻唑和二氢-5H-噻唑[3,2-a]嘧啶化合物，包括其对5-HT1A受体具有亲和力并抑制5-羟色胺和/或去甲肾上腺素的神经再摄取的药用盐，以及其制备方法，含有它们的药物组合物，以及它们在治疗抑郁症、焦虑症、精神病（例如精神分裂症）、迟发性运动障碍、肥胖症、药物成瘾、药物滥用、认知障碍、阿尔茨海默病、强迫性行为、恐慌发作、社交恐惧症、进食障碍（如暴食症、厌食症、吃零食和暴饮暴食）、非胰岛素依赖型糖尿病、高血糖、高脂血症、压力、作为戒烟辅助以及治疗和/或预防癫痫发作、癫痫等神经系统疾病以及存在神经损伤的情况（如中风、脑外伤、脑缺血、头部损伤和出血）中的用途。
• Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors
  作者：Guiping Cai、Wenying Yu、Dongmei Song、Wenda Zhang、Jianpeng Guo、Jiawen Zhu、Yuhao Ren、Lingyi Kong

  DOI：10.1016/j.ejmech.2019.04.024

  日期：2019.7

  STAT3 has been extensively studied as a potential antitumor target. Though studies on regulating STAT3 mainly focus on the inhibition of STAT3 phosphorylation at Tyr705 residue, the phosphorylation at Ser727 residue of STAT3 protein is also closely associated with the mitochondrial import of STAT3 protein. N, N-diethyl-7-aminocoumarin is a fluorescent mitochondria-targeting probe. In this study, a

  STAT3已被广泛研究为潜在的抗肿瘤靶标。尽管关于调节STAT3的研究主要集中在抑制Tyr705残基上的STAT3磷酸化，但是STAT3蛋白的Ser727残基上的磷酸化也与STAT3蛋白的线粒体导入密切相关。N，N-二乙基-7-氨基香豆素是一种荧光的线粒体靶向探针。在这项研究中，通过将N，N-二乙基-7-氨基香豆素荧光团与苯并[ b ]噻吩1，1-二氧化物部分相连，开发了一系列STAT3抑制剂。所有设计的化合物均显示出对癌细胞有效的抗增殖活性。代表性化合物7a主要通过荧光可见的线粒体中积累。化合物7a在Tyr705和Ser727残基均抑制STAT3磷酸化。化合物7a抑制STAT3磷酸化，而对STAT1，JAK2，Src和Erk1 / 2的磷酸化水平没有影响，表明化合物7a具有良好的选择性。此外，化合物7a下调STAT3靶基因Bcl-2和Cyclin D1的表达，增加ROS的产生并显着降低线